DiNardo, Katherine W.
LeBlanc, Thomas W.
Chen, Hui
Article History
Received: 12 January 2023
Accepted: 10 February 2023
First Online: 3 March 2023
Declarations
:
: This is not applicable for this summary.
: This is not applicable for this summary.
: Thomas W. LeBlanc is currently, or has recently been a consultant for AbbVie, Agios/Servier, Astellas, AstraZeneca, BlueNote, BMS/Celgene, CareVive, Flatiron, Genentech, GSK, Novartis, and Pfizer. He has served on recent advisory boards for AbbVie, Agios, and BMS. He has received honoraria from AbbVie, Agios, Astellas, BMS/Celgene, and Incyte for recent speaking engagements. He has also received recent research funding from the American Cancer Society, AstraZeneca, Deverra Therapeutics, Duke University, Jazz Pharmaceuticals, the National Institute of Nursing Research/ National Institutes of Health, and Seattle Genetics.